Suck it up and put up a blow out bid that Sanofi won't match and continue to give Sanofi exclusivity and royalties. BDX would be foolish to ignore UNIS entering the syringe market with their patented passive retractable safety syringe. I am surprised none of the analysts asked about it on the call, but then again, analysts know crap in my opinion.
Strategically, they can't afford to let UNIS build out their planned plant expansion and reach full capacity. They might as well just stop selling syringes. No wonder Buffet sold out his stake - lack of leadership knowing what is going on in their backyard.